-- 蒙特婁銀行(BMO)表示,由於去年春季關稅提前生效的影響,年比數據仍有偏差,美國4月輕型車銷量較去年同期下降5.7%。 該銀行指出,經季節性調整後的年化銷售(SAAR)為1,610萬輛,顯示儘管汽油價格連續數月高企,但需求依然堅挺。 BMO計算得出,5月初汽油價格為每加侖4.46美元,環比上漲超過30美分,日均汽油銷量約為3.75億加侖,這意味著消費者每天比上月多花費約1.3億美元。 該銀行表示,如果燃油價格持續高企,未來幾個月營運成本上升可能會抑制消費者的非必要支出和汽車需求。 BMO指出,加拿大4月新車銷售也放緩,年減幅同樣受到關稅提前生效的影響。銷量下滑至年化181萬輛,較去年同期下降3.9%。 報告補充道,儘管貿易狀況不明朗且汽油價格接近歷史最高水平,但市場表現優於預期。 5月初,加拿大普通汽油均價為每公升1.94加幣。 由於聯邦消費稅暫停徵收至9月(屆時為每公升10加幣),5月初價格較上月上漲約5加分。 BMO指出,值得關注的一個趨勢是,隨著價格更低的車型供應增加,零排放汽車(ZEV)的銷售是否會在今年稍後再次加速成長。加拿大零排放汽車銷售在2月下旬和3月表現強勁,但4月有所降溫。
Related Articles
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%